CCCC
C4 Therapeutics, Inc.NASDAQHealthcare$2.82+4.44%ClosedMarket Cap: $233.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.92
P/S
6.54
EV/EBITDA
-2.04
DCF Value
$-3.03
FCF Yield
-42.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
95.0%
Operating Margin
-320.5%
Net Margin
-292.1%
ROE
-53.8%
ROA
-29.2%
ROIC
-34.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $11.0M | 83.6% | $-23.1M | $-20.5M | $-0.18 | — |
| FY 2025 | $35.9M | 77.8% | $-104.5M | $-105.0M | $-1.27 | — |
| Q3 2025 | $11.2M | 100.0% | $-34.4M | $-32.2M | $-0.44 | — |
| Q2 2025 | $6.5M | 100.0% | $-28.5M | $-26.0M | $-0.37 | — |
| Q1 2025 | $7.2M | 100.0% | $-29.2M | $-26.3M | $-0.37 | — |
| Q4 2024 | $5.2M | 65.9% | $-37.7M | $-34.6M | $-0.49 | — |
| FY 2024 | $35.6M | 100.0% | $-119.6M | $-105.3M | $-1.52 | — |
| Q3 2024 | $15.4M | 86.6% | $-28.2M | $-24.7M | $-0.35 | — |
| Q2 2024 | $12.0M | 83.0% | $-21.4M | $-17.7M | $-0.26 | — |
| Q1 2024 | $3.0M | 100.0% | $-32.2M | $-28.4M | $-0.41 | — |
| Q4 2023 | $3.3M | 48.1% | $-37.4M | $-34.8M | $-0.68 | — |
| FY 2023 | $20.8M | 62.7% | $-139.0M | $-132.5M | $-2.67 | — |